8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Grazoprevir plus elbasvir 12 to 16 weeks is now approved for chronic hepatitis C (CHC) genotype 1, 4, or 6 infection regardless liver disease severity. The current study aims to explore the efficacy and safety of 8-week grazoprevir/elbasvir in HCV-1b patients with mild liver fibrosis
Epistemonikos ID: d896df13abf0f98c24b8146c2b27ae41bcc3e687
First added on: May 20, 2024